

COLLEGE of AMERICAN PATHOLOGISTS

### Less is More

### **Real-World of Digital** Pathology and Al

Diana M Lin, MD, FCAP Dibson D. Gondim, MD, FCAP Eyas M Hattab MD, MBA, FCAP



## Diana Murro Lin MD, FCAP

- Member- Practice Management
  Committee
- PMC Liaison Digital Content Committee
- Associate Professor of Pathology University of Alabama at Birmingham
- Medical Director, AP Division, UAB Highlands Hospital
- CAP State Commissioner for Alabama and Division Commissioner for the Florida Panhandle
- Board certified AP/CP and Cytopathology © College of American Pathologists.



### Eyas M Hattab MD, MBA, FCAP

- Member, Practice Management
  Committee, House of Delegates
- Professor and Chair of Pathology and Laboratory Medicine at University of Louisville
- AP/CP certified with subspecialty fellowships in neuropathology and oncological surgical pathology
- Internationally recognized neuropathologist



### Dibson Dibe Gondim, MD, FACP

- Member of the Artificial Intelligence
  Committee, CAP
- Director of Pathology Informatics and Assistant Professor of Pathology at the University of Louisville
- Certified by the American Board of Pathology in:
  - Anatomic Pathology
  - Neuropathology
  - Clinical Informatics
- Lead on the large-scale digital pathology and Al Initiative at the University of Louisville





The information presented today represents the opinions of the panelists and does not represent the opinion or position of the CAP.

This should not be used as a substitute for professional assistance.

The information in this presentation is provided for educational purposes only and is not legal advice.

### **Topics for Today's Discussion**

- Introduction
- CLIA updates
- Billing
- Real world applications of digital pathology
- Artificial intelligence
- Integrated sign-out dashboard



### What is digital pathology?

- Acquiring and interpreting pathology information from a digitized glass slide •
  - Diagnosis
  - Consultation
  - Teaching
  - Multi-disciplinary conference presentation
  - And so much more!





### **Artificial Intelligence (AI)**



Developing algorithms and models using digital analysis and machine • learning



## Is remote sign-out feasible post COVID?



Yes, you can sign out digital slides without a CLIA certificate for your house or other remote location!



As long as the primary lab meets updated guidelines

Memorandum: "Clinical Laboratory Improvement Amendments of 1988 (CLIA) Post-Public Health Emergency (PHE) Guidance" Center for Clinical Standards and Quality/Quality, Safety & Oversight Group. Centers for Medicare & Medicaid Services. May 11, 2023.

## **Primary site requirements**

- Has CLIA certification and complies with all relevant Federal laws.
- Is certified to perform all the of work performed at the remote site and the laboratory director is responsible for all testing.
- Retains all documentation, including tests performed remotely and list of staff working remotely.
- Indicates remote site location on the reports (coding system ok).

Memorandum: "Clinical Laboratory Improvement Amendments of 1988 (CLIA) Post-Public Health Emergency (PHE) Guidance" Center for Clinical Standards and Quality/Quality, Safety & Oversight Group. Centers for Medicare & Medicaid Services. May 11, 2023.

## Yes, you can code!

- Category III digital CPT codes now available
- Must use whole-slide imaging
- No codes for
  - Education/research
  - Tumor boards/clinical conferences
  - Archiving
  - Validation

### 11

## **Diagnosis, Special Stains and IHC**

Digital Code	In conjunction with
+0751T	88302
+0752T	88304
+0753T	88305
+0754T	88307
+0755T	88309
+0756T	88312
+0757T	88313
+0758T	88314
+0759T	88319
+0760T	88342
+0761T	88341
+0762T	88344
+0763T	88360



## Coming soon on Jan. 1- cytology, expanded surgical and hematology codes

Digital Code	In conjunction with	Digital Code	In conjunction with	Digital Code
+0827T	88104	+0838T	88321	+0849T
+0828T	88106	+0839T	88323	+0850T
+0829T	88108	+0840T	88325	+0851T
+0830T	88112	+0841T	88331	+0852T
+0831T	88141	+0842T	88332	+0853T
+0832T	88160	+0843T	88333	+0854T
+0833T	88161	+0844T	88334	+0855T
+0834T	88162	+0845T	88346	+0856T
+0835T	88172	+0846T	88350	
+0836T	88177	+0847T	88363	
+0837T	88173	+0848T	88365	

In conjunction with
88364
88366
88368
88369
88377
85060
85097
88348

### **Digital Pathology: Real-world** applications

- Not one size fits all •
- Many different applications •
  - Specific operational / logistical function
  - Specific mission (education, research, etc)
  - Improved staffing / access
  - Grow business (referrals, consultations)
- Means to an end! (AI deployment) •





### **BNOUSE COnsultation**

I have an interesting case and would appreciate your expert opinion.

Of course!



~ A: BRAIN

HE

Thank you. Here is the link: https://digitalslide/case

I see. Is there something specific that concerns you?



Actually, yes. I can set the concerning area as the start view. Here: https://digitalslide/case/zoomLevel

Great, I will take a look...





## Inhouse consultation



- Easily communicate in real time!
- No shuffling slides between locations!
- Better turnaround time!

## real time! ween locations!

## **External digital consultation / point of care**

- Using digital pathology for external consultation •
  - Cumbersome physical workflow
    - Extra paperwork
    - Slides packaged / sent
  - Shipping costs and labor add up over time
  - Suboptimal turnaround time
  - **Original slides lost, broken, or never returned**



## **Conferences and Tumor Board**



### **Consensus Conference**





## **Consensus Conference**



- Better attendance!
- No more crowding!











# • Sign in from anywhere!

- Advanced cataloging / organizing
- Automated workflow processes
- Easy data sharing and collaboration
- A tag can be any label! Customizable

### 21



### Tagging through the digital slide viewer

### Pathology Report Internal Comments

ssss/+40+SP23000XXX001001001/pituitary fossa/pitnet, corticotroph type, sparsely granulated, silent

accession 💌	pathologist 🛛 🖵	slide_site 💌	slide_comment	
03-SP-23-XXX	HATTAB, EYAS, MD-PAT	cornea	fungal keratitis	https://
03-SP-23-XXX2	HATTAB, EYAS, MD-PAT	cornea	chronic corneal edema with bullous keratopathy	https://
40-SP-23-XX	HATTAB, EYAS, MD-PAT	clivus	rathke cleft cyst	https://
40-SP-23-XX	HATTAB, EYAS, MD-PAT	sphenoid mass	chordoma	https://
03-SP-23-X3	HATTAB, EYAS, MD-PAT	eyelid	merkel cell carcinoma	https://
40-SP-23-XXX	HATTAB, EYAS, MD-PAT	pituitary fossa	pitnet, corticotroph type, sparsely granulated, silent	https://
40-SP-22-X1	HATTAB, EYAS, MD-PAT	spine	myxopapillary ependymoma	https://

### Tagging through the pathology report to send to a common database

### slide\_url

DigitalSlideViewer/launchCase DigitalSlideViewer/launchCase DigitalSlideViewer/launchCase DigitalSlideViewer/launchCase DigitalSlideViewer/launchCase DigitalSlideViewer/launchCase

 $\overline{\Psi}$ 

resident lecture case of interest potential GSU tumor board to photograph

### UPDATED INTEGRATED DIAGNOSIS

### FINAL INTEGRATED DIAGNOSIS:

Solitary fibrous tumor, CNS WHO grade 2

### HISTOLOGIC DIAGNOSIS:

Spindle cell tumor

### RELEVANT ANCILLARY INFORMATION:

STAT6 (IHC): Positive Consensus Methylation Profiling Class: Solitary fibrous tumor, CNS WHO grade 2 (see Comment)

### CNS WHO GRADE:

WHO grade 2



A - 001 - 001 **Block-Description:** Left Lateral Orbital Mass Case: Surgical Pathology

A - 001 - 002 **Block-Description:** Left Lateral Orbital Mass Case: Surgical Pathology

### Tagging through other sources



Block: A - 002 - 001 **Block-Description:** Left Lateral Orbital Mass

Case: Surgical Pathology

## **DP Implementation is not without challenges**

- Cost/Business case (initial investment and ongoing maintenance)
- **Regulatory** issues
- Buy in (C-suite, pathologists, clinicians, staff, etc)
- **Requires significant workflow adjustments**
- **Requires IT support, clinical information management, etc**
- Vulnerable to interruptions
- Scanning/viewing limitations
  - Cytology, bone marrows, H. pylori, mitoses, polarization, etc
- Requires a QA program
  - Failure rate, re-scanning  $\bigcirc$



### **Artificial Intelligence**



- **Basic requirements** •
- Common AI-based systems for histopathology •
- Ensuring trustworthiness in AI pathology ightarrow
- Maximizing productivity •
- AI + DP interoperability •





### **Computational pathology** (AI-based approaches)

**High-quality histology** 

## Pathologists: The pillars of precision medicine

- Masters of doing more with less
- **Efficiency masters** 
  - Unparalleled skill in maximizing precision with fixed resources
- **Precision medicine champions** 
  - Crucial to the seamless integration of advanced diagnostics into patient care
- **Escalating duties** 
  - Steering through intricate molecular diagnostics landscape
  - Absorbing rapid growth in medical knowledge
  - Adapting to a tight web of regulatory requirements
- Sustainability check
  - Evaluating the potential for overload
  - Necessity of innovative tools to support pathologists' expanding roles 0







28

## The role of Al in pathology

- Al as a tool
  - Requires careful exploration and mastery
  - Still in early stages—potential unknown risks
  - Our duty to understand and mitigate risks
  - Robust DP Infrastructure is critical

### Implementation challenges

- Substantial effort for AI system deployment
- Not universally established infrastructure
- Productivity and AI
  - Al deployment alone ≠ guaranteed productivity gains
  - True potential lies in AI + knowledge + optimal implementation

### 29

## **Common Al-based systems for histopathology**

- **Classification & detection** #1
- **Digital biomarker and virtual staining** #2
- Image-based predictive/prognostic model #3

(Note: This list is not exhaustive)



## **#1 Classification & detection systems**

- Tumor detection, quantification, and grading
  - Advanced algorithms for tumor analysis
  - Example: solutions for prostate and breast biopsies
- Metastasis detection
  - Automated detection of lymph node metastases
- Mitotic activity assessment
  - Al-driven counting of mitotic figures
- Result verification
  - Tools for pathologists to confirm Al findings
  - Visualization techniques
    - Use of masks and heatmaps for Al-histology correlation

### 31

## **#1 Example: Al for cancer identification,** quantification, grading, and PNI detection



	20x ~	<b>√</b> ~	/ ~ 🚺
1 1 2 10 1 1 1 1	10		
1	AI PAIGE PROSTATE		×
	RUO		
100	Focus of Interest		e
2	Invasive Carcinoma		
	Invasive Carcinoma		62.71 %
2	Length		8.65 mm
3	Pattern 4		100.00 %
1	Gleason Score		4 + 4 = 8
	Perineural Invasion		
-			

## **#1 Example: AI for kidney tumor classification with** heatmaps



### More examples can be found here: http://aistain.com

Gondim DD, Al-Obaidy KI, Idrees MT, Eble JN, Cheng L. Artificial intelligence-based multi-class histopathologic classification of kidney neoplasms. J Pathol Inform. 2023 Feb 16;14:100299. doi: 10.1016/j.jpi.2023.100299. PMID: 36915914; PMCID: PMC10006494.

© College of American Pathologists.

## **#2 Digital biomarker and virtual staining**

### Enhanced turnaround time

Accelerate result availability, bypassing the wait for traditional staining or other ancillary studies. 0

### **Resource efficiency**

Decreases dependence on physical instruments, supplies and specialized personnel Ο

### Consideration of risks

- Validation could be performed based on gold standard Ο
- Challenge prospective monitoring Ο
- Limited literature about real world deployment Ο

## **#2 Example: Virtual trichrome for liver**



Naglah A, Khalifa F, El-Baz A, Gondim D. Conditional GANs based system for fibrosis detection and quantification in hematoxylin and eosin whole slide images. Medical Image Analysis. 2022 Oct 1;81:102537.

Systems and methods for digital transformation of medical images and fibrosis detection Provisional patent, US Patent App. 17/845,880 El-Baz, A.S., Gondim, D., Naglah, A., and Khalifa, F.

## **#3 Image-based predictive/prognostic models**

- **Optimal treatment guidance** 
  - Utilizing AI to recommend the most effective treatment options tailored to individual patient profiles
- **Prognosis group stratification** 
  - Al algorithms assist in categorizing patients into prognosis groups, enabling personalized care plans  $\bigcirc$
- Case study: ArteraAl prostate test
  - An example of Al's application in providing prognostic insights for prostate cancer management
- **Verification challenges** 
  - The current limitations in secondary methods for independent result confirmation  $\bigcirc$



## **Ensuring trustworthiness in AI pathology**

- Critical role of validation
  - Validation protocols are paramount to establish the reliability of AI results Ο
- Pathologist oversight (human-in-the-loop)
  - Pathologist in the decision-making loop to adjudicate AI findings Ο
  - Pathologist oversight not possible for biomarkers, virtual staining, and predictive/prognostic  $\bigcirc$ assessments
- Adjudication workflow integration
  - Incorporating a structured workflow for pathologists to review and adjust AI outcomes

### **Risk mitigation**

Addressing the potential for false negatives or positives, which could inadvertently increase the  $\bigcirc$ pathologist's workload

37

## **DP + AI Interoperability**

- Full-spectrum integration (ideal)
  - $\circ$  EHR + LIS + DP + AI
  - Lab-centric control (LIS + DP + AI) 0
- Efficiency in case management
  - Eliminates the need for manual retrieval across different applications  $\bigcirc$
  - Allows order placement from image management systems (IMS) to laboratory information system (LIS) Ο
  - Easy export of images from digital pathology (DP) to LIS Ο

### Seamless asset tracking

Simplifies the monitoring of asset status, improving turnaround times and resource allocation Ο

## **DP + AI Interoperability**



### **Standard-based interfaces**

### Potential to plug and play (NOT A REALITY IN THE MARKET)



### **Custom interfaces** (Not scalable – Not sustainable)



### **Custom interfaces** (Not scalable – Not sustainable)



### **Custom interfaces** (Not scalable – Not sustainable)



## **Example: LIS + DP + AI Interoperability**





© College of American Pathologists.



### Current interface architecture at UL Health

## **Conclusion & take-home messages**

- DP and AI offer the potential for enhanced accuracy and productivity
- High-quality histology and lab operational efficiency are paramount
- Leveraging Al's full potential
  - Expertise, exploration, validation, and interoperability
- Adjudication risk
  - Suboptimal accuracy = workflow complexities and higher workloads
- Interoperability risk
  - Inadequate interoperability = workflow complexities and higher workloads



45



### **Membership**

Did you find this information useful?

This program was funded by your CAP membership. Please be sure to keep your membership current so we can continue to bring timely and relevant resources like this to you.

Visit cap.org to renew your membership or email membership@cap.org.



### **Pathology Business Fundamentals**

Essential online courses to help grow your management skills to lead your practice



- **1.** Relative Value Units (RVU's)—Understanding the Basics
- 2. How Pathology Practices Get Paid
- **3.** Revenue Cycle Management
- **4.** Analysis and Interpretation of Billing Reports
- **5.** Basic Practice Cost Analysis
- 6. Capacity Management and Workflow Analysis
- 7. Basic Contracting and Fee Analysis
- 8. Basic Budget Development



Learn more and register

48

### **Additional Resources**

**Practice Management** 

o <u>https://www.cap.org/member-resources/practice-management</u>

**Practice Management Articles** 

https://www.cap.org/member-resources/articles/category/practice-management Ο

## We value your feedback!



If after attending this discussion and later you applied any of what you learned to your practice, please share your feedback of how it worked for your practice at https://www.cap.org/member-resources/practice-management/practice-managementinquiry-form



Watch for the session evaluation form. Your feedback is important!